Bank of San Francisco (BSFO)

Ligand Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-	6.54	6.93	5.86	8.99	4.66
Depreciation & Amortization	-	0.25	0.25	0.14	0.13	0.13
Gain (Loss) on Sale of Assets	-	-	-	-	0	-
Provision for Credit Losses	-	-0.18	0.29	3.12	0.1	2.73
Accrued Interest Receivable	-	0.08	1.52	-5.9	1.26	-1.02
Other Operating Activities	-	-0.47	-0.41	-0.52	-1.28	2.15
Operating Cash Flow	-	7.69	9.41	7.98	8.62	8.15
Operating Cash Flow Growth	-	-18.21%	17.92%	-7.43%	5.69%	73.61%
Capital Expenditures	-	-0.05	-0.45	-1.35	-0.07	-0.05
Investment in Securities	-	-23.85	-	-	-	-
Net Decrease (Increase) in Loans Originated / Sold - Investing	-	-5.43	19.65	-17.98	42.09	-228.99
Other Investing Activities	-	-	-0.24	-0.25	-0.88	-0.3
Investing Cash Flow	-	-29.34	18.97	-19.58	41.15	-229.35
Long-Term Debt Issued	-	-	-	-	31.84	99.17
Long-Term Debt Repaid	-	-	-	-	-121.62	-9.39
Net Debt Issued (Repaid)	-	-	-	-	-89.78	89.78
Net Increase (Decrease) in Deposit Accounts	-	-4.69	13.14	-19.5	6.12	182.84
Financing Cash Flow	-	-4.69	13.14	-19.5	-83.66	272.62
Net Cash Flow	-	-26.33	41.52	-31.1	-33.89	51.42
Free Cash Flow	-	7.64	8.96	6.63	8.55	8.1
Free Cash Flow Growth	-	-14.73%	35.20%	-22.50%	5.53%	80.91%
Free Cash Flow Margin	-	30.23%	40.07%	32.44%	35.64%	49.16%
Free Cash Flow Per Share	-	3.63	4.30	3.23	4.19	3.99
Cash Interest Paid	-	8.79	7.03	1.54	1.25	1.72
Cash Income Tax Paid	-	2.74	2.34	3.23	4.14	2.77

Source: S&P Global Market Intelligence. Banks template. Financial Sources.